Core Viewpoint - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapies by the National Medical Products Administration, indicating a significant advancement in the treatment of advanced or metastatic pancreatic cancer with KRAS G12D mutations [1] Group 1 - The HRS-4642 injection is used in combination with gemcitabine and albumin-bound paclitaxel for first-line treatment [1]